|
|
|
|
|
|
|
|
|
03.06.25 - 22:33
|
Fennec Announces Results of Annual Meeting (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025....
|
|
|
21.05.25 - 15:30
|
Fennec - A Sound Case For Long-Term Growth? (RTTNews)
|
|
|
Shares of Fennec Pharmaceuticals Inc. (FENC) touched a new 52-week high of $8.26 yesterday, driven by the company's optimized sales strategy for its lead product, Pedmark, and its successful expansion into additional markets....
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.25 - 22:18
|
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.03.25 - 22:24
|
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results....
|
|
|
|
|
10.02.25 - 13:01
|
Norgine launches sodium thiosulfate injection in Germany (PBR)
|
|
|
In March last year, Fennec Pharmaceuticals entered an exclusive licensing agreement, granting Norgine commercialisation rights for the injection in Australia, New Zealand, and Europe. Under this agreement, Fennec
The post Norgine launches sodium thiosulfate injection in Germany appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
